(CHCT) Community Healthcare Trust - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US20369C1062
Medical Offices, Ambulatory Centers, Specialty Clinics
Dividends
| Dividend Yield | 12.33% |
| Yield on Cost 5y | 5.63% |
| Yield CAGR 5y | 2.29% |
| Payout Consistency | 100.0% |
| Payout Ratio | 288.1% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 29.8% |
| Value at Risk 5%th | 47.3% |
| Relative Tail Risk | -3.57% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.21 |
| Alpha | -16.05 |
| CAGR/Max DD | -0.27 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.511 |
| Beta | 0.434 |
| Beta Downside | 0.565 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.60% |
| Mean DD | 38.42% |
| Median DD | 40.44% |
Description: CHCT Community Healthcare Trust October 24, 2025
Community Healthcare Trust, Inc. (NYSE: CHCT) is a health-care focused REIT that acquires and manages income-producing properties used for outpatient services. As of March 31 2025 it owned roughly $1.2 billion of real estate across 201 properties in 36 states, encompassing about 4.5 million sq ft of clinical space.
Recent market data shows CHCT’s occupancy has averaged ≈ 95 % over the past 12 months, and its FY 2024 funds-from-operations (FFO) grew ≈ 7 % YoY, reflecting strong demand for outpatient venues amid an aging U.S. population and the industry-wide shift from inpatient to ambulatory care. The REIT’s weighted-average lease term remains near 9 years, providing cash-flow stability, while cap rates for health-care properties have compressed to the low-5 % range, indicating investor confidence but also heightened sensitivity to rising interest rates.
For a deeper, data-driven view of CHCT’s valuation dynamics, you may want to explore the analytics platform ValueRay, which aggregates sector-specific metrics and scenario modeling tools.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-7.49m TTM) > 0 and > 6% of Revenue (6% = 7.16m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -192.4% (prev -75.15%; Δ -117.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 56.6m > Net Income -7.49m (YES >=105%, WARN >=100%) |
| Net Debt (530.8m) to EBITDA (62.9m) ratio: 8.43 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.9m) change vs 12m ago 1.03% (target <= -2.0% for YES) |
| Gross Margin 80.64% (prev 61.82%; Δ 18.81pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 12.12% (prev 11.78%; Δ 0.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.72 (EBITDA TTM 62.9m / Interest Expense TTM 26.4m) >= 6 (WARN >= 3) |
Altman Z'' -1.68
| (A) -0.23 = (Total Current Assets 48.4m - Total Current Liabilities 277.9m) / Total Assets 987.3m |
| (B) 0.08 = Retained Earnings (Balance) 76.3m / Total Assets 987.3m |
| (C) 0.02 = EBIT TTM 18.9m / Avg Total Assets 984.5m |
| (D) -0.51 = Book Value of Equity -288.1m / Total Liabilities 560.4m |
| Total Rating: -1.68 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.37
| 1. Piotroski 3.50pt |
| 2. FCF Yield 3.82% |
| 3. FCF Margin 31.39% |
| 4. Debt/Equity 1.25 |
| 5. Debt/Ebitda 8.43 |
| 6. ROIC - WACC (= -2.21)% |
| 7. RoE -1.66% |
| 8. Rev. Trend 91.85% |
| 9. EPS Trend -53.28% |
What is the price of CHCT shares?
As of December 14, 2025, the stock is trading at USD 15.30 with a total of 159,940 shares traded.
Over the past week, the price has changed by +0.07%, over one month by +5.59%, over three months by +0.82% and over the past year by -5.14%.
Over the past week, the price has changed by +0.07%, over one month by +5.59%, over three months by +0.82% and over the past year by -5.14%.
Is CHCT a buy, sell or hold?
Community Healthcare Trust has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy CHCT.
- Strong Buy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CHCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.8 | 16.3% |
| Analysts Target Price | 17.8 | 16.3% |
| ValueRay Target Price | 15.2 | -0.8% |
CHCT Fundamental Data Overview December 05, 2025
Market Cap USD = 448.4m (448.4m USD * 1.0 USD.USD)
P/E Forward = 37.3134
P/S = 3.751
P/B = 1.0506
Beta = 0.749
Revenue TTM = 119.3m USD
EBIT TTM = 18.9m USD
EBITDA TTM = 62.9m USD
Long Term Debt = 274.1m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0m USD (from shortTermDebt, last quarter)
Debt = 534.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 530.8m USD (from netDebt column, last quarter)
Enterprise Value = 979.2m USD (448.4m + Debt 534.1m - CCE 3.38m)
Interest Coverage Ratio = 0.72 (Ebit TTM 18.9m / Interest Expense TTM 26.4m)
FCF Yield = 3.82% (FCF TTM 37.4m / Enterprise Value 979.2m)
FCF Margin = 31.39% (FCF TTM 37.4m / Revenue TTM 119.3m)
Net Margin = -6.28% (Net Income TTM -7.49m / Revenue TTM 119.3m)
Gross Margin = 80.64% ((Revenue TTM 119.3m - Cost of Revenue TTM 23.1m) / Revenue TTM)
Gross Margin QoQ = 80.76% (prev 80.80%)
Tobins Q-Ratio = 0.99 (Enterprise Value 979.2m / Total Assets 987.3m)
Interest Expense / Debt = 1.32% (Interest Expense 7.08m / Debt 534.1m)
Taxrate = -0.0% (0.0 / -3.18m)
NOPAT = 18.9m (EBIT 18.9m * (1 - -0.00%))
Current Ratio = 0.17 (Total Current Assets 48.4m / Total Current Liabilities 277.9m)
Debt / Equity = 1.25 (Debt 534.1m / totalStockholderEquity, last quarter 426.8m)
Debt / EBITDA = 8.43 (Net Debt 530.8m / EBITDA 62.9m)
Debt / FCF = 14.17 (Net Debt 530.8m / FCF TTM 37.4m)
Total Stockholder Equity = 450.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.76% (Net Income -7.49m / Total Assets 987.3m)
RoE = -1.66% (Net Income TTM -7.49m / Total Stockholder Equity 450.5m)
RoCE = 2.61% (EBIT 18.9m / Capital Employed (Equity 450.5m + L.T.Debt 274.1m))
RoIC = 1.98% (NOPAT 18.9m / Invested Capital 953.5m)
WACC = 4.19% (E(448.4m)/V(982.6m) * Re(7.61%) + D(534.1m)/V(982.6m) * Rd(1.32%) * (1-Tc(-0.0)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.82%
[DCF Debug] Terminal Value 77.10% ; FCFE base≈34.7m ; Y1≈32.1m ; Y5≈29.1m
Fair Price DCF = 18.39 (DCF Value 523.5m / Shares Outstanding 28.5m; 5y FCF grow -9.43% → 3.0% )
EPS Correlation: -53.28 | EPS CAGR: -41.91% | SUE: -0.26 | # QB: 0
Revenue Correlation: 91.85 | Revenue CAGR: 7.81% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.47 | Chg30d=+0.020 | Revisions Net=-1 | Growth EPS=+295.8% | Growth Revenue=+5.8%
P/E Forward = 37.3134
P/S = 3.751
P/B = 1.0506
Beta = 0.749
Revenue TTM = 119.3m USD
EBIT TTM = 18.9m USD
EBITDA TTM = 62.9m USD
Long Term Debt = 274.1m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0m USD (from shortTermDebt, last quarter)
Debt = 534.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 530.8m USD (from netDebt column, last quarter)
Enterprise Value = 979.2m USD (448.4m + Debt 534.1m - CCE 3.38m)
Interest Coverage Ratio = 0.72 (Ebit TTM 18.9m / Interest Expense TTM 26.4m)
FCF Yield = 3.82% (FCF TTM 37.4m / Enterprise Value 979.2m)
FCF Margin = 31.39% (FCF TTM 37.4m / Revenue TTM 119.3m)
Net Margin = -6.28% (Net Income TTM -7.49m / Revenue TTM 119.3m)
Gross Margin = 80.64% ((Revenue TTM 119.3m - Cost of Revenue TTM 23.1m) / Revenue TTM)
Gross Margin QoQ = 80.76% (prev 80.80%)
Tobins Q-Ratio = 0.99 (Enterprise Value 979.2m / Total Assets 987.3m)
Interest Expense / Debt = 1.32% (Interest Expense 7.08m / Debt 534.1m)
Taxrate = -0.0% (0.0 / -3.18m)
NOPAT = 18.9m (EBIT 18.9m * (1 - -0.00%))
Current Ratio = 0.17 (Total Current Assets 48.4m / Total Current Liabilities 277.9m)
Debt / Equity = 1.25 (Debt 534.1m / totalStockholderEquity, last quarter 426.8m)
Debt / EBITDA = 8.43 (Net Debt 530.8m / EBITDA 62.9m)
Debt / FCF = 14.17 (Net Debt 530.8m / FCF TTM 37.4m)
Total Stockholder Equity = 450.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.76% (Net Income -7.49m / Total Assets 987.3m)
RoE = -1.66% (Net Income TTM -7.49m / Total Stockholder Equity 450.5m)
RoCE = 2.61% (EBIT 18.9m / Capital Employed (Equity 450.5m + L.T.Debt 274.1m))
RoIC = 1.98% (NOPAT 18.9m / Invested Capital 953.5m)
WACC = 4.19% (E(448.4m)/V(982.6m) * Re(7.61%) + D(534.1m)/V(982.6m) * Rd(1.32%) * (1-Tc(-0.0)))
Discount Rate = 7.61% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.82%
[DCF Debug] Terminal Value 77.10% ; FCFE base≈34.7m ; Y1≈32.1m ; Y5≈29.1m
Fair Price DCF = 18.39 (DCF Value 523.5m / Shares Outstanding 28.5m; 5y FCF grow -9.43% → 3.0% )
EPS Correlation: -53.28 | EPS CAGR: -41.91% | SUE: -0.26 | # QB: 0
Revenue Correlation: 91.85 | Revenue CAGR: 7.81% | SUE: 0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.10 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.47 | Chg30d=+0.020 | Revisions Net=-1 | Growth EPS=+295.8% | Growth Revenue=+5.8%
Additional Sources for CHCT Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle